Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

As healthcare pushes forward in digital transformation, AI has emerged as a critical tool in optimizing electronic medical ...